ICIs indications approved by FDA and EMA
| Drug | FDA indications | EMA indications |
|---|---|---|
| Ipilimumab | MelanomaNon-small cell lung cancer Renal cell carcinoma | MelanomaNon-small cell lung cancer Renal cell carcinoma data |
| Nivolumab | MelanomaNon-small cell lung cancer Small cell lung cancer Renal cell cancerClassical Hodgkin’s lymphomaSquamous cell of esophagus or head and neck Urothelial cancerColorectal cancer with microsatellite instability or mismatch-repair deficiencyHepatocellular carcinoma | MelanomaNon-small cell lung cancer Renal cell cancerClassical Hodgkin’s lymphomaSquamous cell of esophagus or head and neck Urothelial cancer |
| Pembrolizumab | MelanomaNon-small cell lung cancer Squamous cell of the head and neck Classical Hodgkin’s lymphoma Urothelial cancerGastric cancer Esophageal cancer Cervical cancer Renal cell carcinomaHepatocellular carcinomaColorectal cancer with microsatellite instability or mismatch-repair deficiency | MelanomaNon-small cell lung cancer Squamous cell of the head and neck Classical Hodgkin’s lymphoma Urothelial cancerColorectal cancer with microsatellite instability or mismatch-repair deficiency |
| Cemiplimab | Cutaneous cell carcinoma | Cutaneous cell carcinoma |
| Atezolizumab | Urothelial carcinomaNon-small cell lung cancer Small-cell lung cancer Breast cancer Hepatocellular carcinoma | Urothelial carcinomaNon-small cell lung cancer Small-cell lung cancer Breast cancer Hepatocellular carcinoma |
| Avelumab | Merkel cell carcinoma Urothelial carcinomaRenal Cell carcinoma | Merkel cell carcinoma Urothelial carcinomaRenal cell carcinoma |
| Durvalumab | Urothelial carcinomaNon-small cell lung cancer | Non-small cell lung cancer |